How to buy Heat Biologics stock

Heat Biologics Inc. is a biotechnology business based in the US. Heat Biologics shares (HTBX) are listed on the NASDAQ and all prices are listed in US Dollars. Heat Biologics employs 49 staff and has a trailing 12-month revenue of around $2.1 million.

Client disclaimer: US Brokerage services through eToro USA Securities Inc, member of FINRA, SIPC. Crypto assets through eToro USA LLC.

Heat Biologics stock price (NASDAQ: HTBX)

Use our graph to track the performance of HTBX stocks over time.

Heat Biologics shares at a glance

• Key figures

Information last updated 2022-08-28.

Latest market close	$2.55
52-week range	$1.60 - $6.12
50-day moving average more info button	$2.57
200-day moving average more info button	$4.11
Wall St. target price	$11.38
PE ratio more info button	N/A
Dividend yield more info button	$0 (0%)
Earnings per share (TTM) more info button	$-1.41

Buy Heat Biologics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Heat Biologics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Heat Biologics price performance over time

Historical closes compared with the close of $2.55 from 2022-07-01

1 week (2022-09-19)	N/A
1 month (2022-08-26)	N/A
3 months (2022-06-30)	2.55
6 months (2022-03-30)	-17.48%

1 year (2021-09-30)	-57.14%
2 years (2020-09-30)	105.65%
3 years (2019-09-30)	425.12%
5 years (2017-09-29)	290.45%

Heat Biologics financials

Revenue TTM	$2.1 million
Gross profit TTM	$-16,708,472
Return on assets TTM	-17.1%
Return on equity TTM	-31.12%
Profit margin	0%
Book value	$4.41
Market capitalisation more info button	$72.6 million

TTM: trailing 12 months

Heat Biologics share dividends

We're not expecting Heat Biologics to pay a dividend over the next 12 months.

Have Heat Biologics's shares ever split?

Heat Biologics's shares were split on a 1:7 basis on 10 December 2020. So if you had owned 7 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Heat Biologics shares – just the quantity. However, indirectly, the new 600% higher share price could have impacted the market appetite for Heat Biologics shares which in turn could have impacted Heat Biologics's share price.

Heat Biologics share price volatility

Over the last 12 months, Heat Biologics's shares have ranged in value from as little as $1.6 up to $6.12. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Heat Biologics's is 0.3049. This would suggest that Heat Biologics's shares are less volatile than average (for this exchange).

Heat Biologics overview

NightHawk Biosciences, Inc. , an integrated biopharmaceutical company, engages in the development of immune therapies and vaccines. The company's therapies are used to modulate the immune system against various diseases, including cancer and infectious diseases. Its gp96 platform, including ImPACT, an allogenic cell-based, T-cell-stimulating platform that functions as an immune activator to stimulate and expand T-cells; and ComPACT, which delivers antigen driven T-cell activation and specific co-stimulation in a single product. The company develops HS-110, which has completed enrollment in a Phase II clinical trial to treat patients with advanced non-small cell lung cancer; and HS-130 that is in Phase I clinical trial for the treatment of advanced solid tumors. Its products also include PTX-35, a novel T-cell co-stimulator agonist antibody targeting DR3/TNFRSF25 that is in Phase I clinical trial; DR3/TNFRSF25 for various immunotherapy approaches; and COVID-19 vaccine, which is in preclinical stage. The company has a collaboration with Dr.

Frequently asked questions

What percentage of Heat Biologics is owned by insiders or institutions?
Currently 5.201% of Heat Biologics shares are held by insiders and 10.76% by institutions. How many people work for Heat Biologics?
Latest data suggests 49 work at Heat Biologics. When does the fiscal year end for Heat Biologics?
Heat Biologics's fiscal year ends in December. Where is Heat Biologics based?
Heat Biologics's address is: 627 Davis Drive, Morrisville, NC, United States, 27560 What is Heat Biologics's ISIN number?
Heat Biologics's international securities identification number is: US42237K4094 What is Heat Biologics's CUSIP number?
Heat Biologics's Committee on Uniform Securities Identification Procedures number is: 42237K102